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ABSTRACT 
 
 
Purpose 
To evaluate the diagnostic performance of simultaneous FDG-PET/MR 
compared to FDG-PET/CT in non-Hodgkin’s and Hodgkin’s lymphoma. 
 
Methods 
This cross-sectional study included fifteen patients with a confirmed diagnosis of 
NHL or HL who had completed a clinical FDG-PET/CT and a same day research 
FDG-PET/MR. SUVmax for FDG-avid lesions were measured for each imaging 
modality, as well as ADC from FDG-PET/MR. Strength of correlation between 
variables was measured using the Spearman rank correlation coefficient (rs). The 
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overall radiation exposure dose was also calculated for a clinical FDG-PET/CT 
and compared to the radiation dose level remaining at time of FDG-PET/MR. 
 
Results 
Thirty-seven concordant FDG-avid lesions were identified on both PET/CT and 
PET/MR imaging. SUVmax from FDG-PET/MR versus FDG-PET/CT 
demonstrated a strongly positive correlation (rs=0.84 (0.71, 0.92); p<0.0001). 
There was no correlation found between ADCmin and SUVmax from FDG-
PET/MR (r=0.35(-0.07, 0.66); p=0.09). The overall radiation exposure from one 
FDG-PET/CT was 24.07±6.06mSv (range: 17.67-33.84mSv) compared to the 
decay-corrected radiation dose at FDG-PET/MR (2.87±0.92mSv (range: 1.86-
5.90mSv)). 
 
Conclusion 
FDG-PET/MR offers a comparable whole body staging examination with an 
improved radiation safety profile in NHL and HL patients when based on the 
maximum standardized uptake value. 
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 1 
INTRODUCTION 
 
Lymphoma 
Lymphoma is a type of cancer that occurs when certain immune cells called 
lymphocytes begin to grow or behave abnormally within the blood and is 
therefore termed a hematologic malignancy [1, 2]. The two major types of 
lymphocytes are B and T cells. Both play a role in recognizing and clearing the 
body of infectious organisms and abnormal cells. Lymphocytes circulate 
throughout the body through a network of vessels containing a clear fluid called 
lymph. The lymphatic system includes the lymph nodes, thymus, tonsils, spleen, 
bone marrow, and the lymphoid tissue of the digestive system. Thousands of 
lymph nodes are scattered throughout the body, and each filters out microbial 
organisms from the lymph fluid. When lymphocytes begin to rapidly grow and 
divide, they often collect in one or more lymph nodes and ultimately form a mass 
called a tumor; however, it is possible for other non-lymph nodal sites to be 
affected such as the liver, spleen, brain, skin, digestive system, and bone marrow 
[1]. Due to the lymphatic system, lymphomas may essentially spread to any area 
of the body[1, 2]. 
 
There are two major types of lymphoma: Hodgkin’s lymphoma (HL) and non-
Hodgkin’s lymphoma (NHL). Lymphoma symptoms include, but are not limited to 
lymphadenopathy, night sweats, fever, weight loss, fatigue, and itching. While 
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both classifications of lymphoma often occur in the same locations within the 
body, they may present with the same symptoms, and also appear similar upon 
physical examination; they are differentiable at the microscopic level. [1-3].  
 
Hodgkin’s lymphoma originates from a specific abnormal B cell lineage and 
includes 5 subtypes. At the microscopic level, Hodgkin cells are characterized by 
the presence of Reed-Sternberg (RS) cells which are readily identified by their 
large size and numerous and/or bi-lobed nuclei. HL typically follows a bimodal 
distribution (ages 15-34 years and above 55 years)[4]. Non-Hodgkin’s lymphoma 
includes over 60 different subtypes, and is essentially identified as any 
lymphoma that does not involve RS cells. Due to this broad inclusion criteria, 
NHL is far more common in the United States, comprising over 85% of new 
lymphoma cases [5]. The incidence of NHL increases with age, with 50% of 
cases occurring in patients 65 years and older. Both NHL and HL are more 
prevalent in Caucasians and men in developed countries; however, there is no 
explanation for this observed prevalence. The overall 5-year period for survival is 
69% for lymphoma; however, this figure can be as low as 10% for certain B and 
T cell NHL subtypes [5].   
 
Similar to most types of cancer, therapeutic strategies and prognoses depend 
heavily on initial tumor staging [6]. Staging is a method to describe the extent and 
severity of cancer within the body. Prior to the start of the twenty-first century, 
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computed tomography (CT) was considered the integral method for evaluation 
and staging of lymphomas [7].  
  
Imaging Modalities 
Computed Tomography (CT) 
CT uses computer-processed X-rays (ionizing radiation) to image the body in 
‘slices’. Due to its high-contrast resolution, CT is able to detect density 
differences in tissue that are as small as 1%. This is particularly advantageous 
for malignancies such as lymphoma, which exhibit increased cellularity (cellular 
density); although, CT is currently unable to distinguish between a viable tumor 
and a necrotic or fibrotic mass that remains after treatment [8]. This is an issue 
when trying to determine a patient’s response to treatment, or risk of relapse 
(cancer recurrence) after chemotherapy [8]. However, with the emergence of 
positron emission tomography (PET) with [18F]fluordeoxyglucose (FDG)  in the 
late 1990s, oncologists now have an imaging tool that is able to overcome CT’s 
specificity limitation.  
 
Positron Emission Tomography (PET) 
PET is a form of nuclear/molecular imaging that is able to produce a three-
dimensional tomographic image of functional processes within the body. When 
combined with FDG, PET is a critical tool for staging lymphoma patients [9]. FDG 
is a radioactive tracer with a chemical structure similar to glucose (sugar) that is 
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absorbed by “metabolically active” tissues such as malignant masses, and is 
unable to leave cells upon entering.  During the PET scan, the F-18 isotopes 
decay and emit positrons (positively charged particle), which annihilate (collide) 
with electrons (negatively charged particles), releasing pairs of 511 keV photons 
(high energy particles) which are detected by the PET scanner. The more FDG 
that is taken up or absorbed by a specific tissue, the stronger the signal will be 
that is emitted. The signal intensity is indicative of the metabolic activity of the 
tumor. As a semi-quantitative measure, the PET signal is usually converted to 
standardized uptake values, which are obtained by normalizing the measured 
activity to the specific activity (injected dose over patient weight). One 
measurement of uptake is the maximum standardized uptake value (SUVmax), 
which is routinely used for clinical purposes [10]. FDG-PET scans are 
recommended before (initial staging), during, or after (restaging) treatment 
depending on the type and biological characteristics (fast growing vs. slow 
growing) of lymphoma [9]. Although PET is highly sensitive and specific for 
lymphoma (metabolically), it is unable to provide the precise anatomical 
information of CT [8].  
 
Early interim FDG-PET (between chemotherapy cycles) has shown prognostic 
value in both NHL and HL[11-14]. In HL patients, early interim FDG-PET and 
SUVmax were identified as strong and independent predictors of progression free 
survival (PFS), and was superior to CT alone [14]. The two-year PFS in HL 
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patients was 100% for those with SUVmax < 3 g/ml [14]. In contrast, a positive 
early interim FDG-PET was highly predictive for progression in HL patients with 
advanced or extranodal disease. Similar results for predicting treatment failure 
and PFS have been reported for NHL patients [11, 12, 15, 16]. For primary 
staging, FDG-PET results, compared to CT alone, influenced disease staging in 
15-20% of NHL patients, and altered clinical management in 5-10% [17, 18].  
 
Hybrid PET/CT 
In 2001, PET was combined with CT into a hybrid scanner called PET/CT [19]. 
This imaging modality combines the metabolic information provided by PET with 
the anatomical information provided by CT in order to localize the specific area of 
the body that exhibits FDG uptake. In addition, the combination of PET with CT 
has been able to address the issue of attenuation correction. Attenuation refers 
to signals (or coincidence events) that are lost (not recorded by PET detectors) 
due to body absorption or scattering. Attenuation correction is required for both 
qualitative and quantitative PET data analysis. Without attenuation correction, 
falsely intense or reduced FDG activity can be detected. PET-CT data is 
corrected for attenuation by converting the standard CT unitsa to linear 
attenuation coefficients on a slice-by-slice basis. An attenuation map is created 
based on density differences which are obtained from the CT component of the 
scan. This, in turn, also allows for “co-registration” in which PET images are 
spatially correlated with CT images. In the last decade, PET-CT has replaced CT 
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as the standard of care for staging and assessing response to treatment in 
lymphoma [9, 20] and many other malignancies (e.g. lung, childhood 
malignancies, colon cancer, and ovarian/cervical malignancies). Although PET-
CT offers several advantages over the two separate imaging modalities, it is not 
without its own limitations.  
 
Due to the need for numerous PET-CT examinations in a clinical oncology 
setting (initial staging, restaging, follow up), the amount of ionizing radiation 
received from each examination is a concern for patients with a good prognosis 
(such as lymphoma), and in particular, pediatric patients [21]. Numerous studies 
of atomic bomb survivors have shown a positive linear relationship between risk 
of solid cancer and radiation dose [22-25]. Furthermore, children are more 
radiosensitive (more susceptible to the harmful effects of ionizing radiation) than 
adults [25]. Based on the 2007 CT usage rates in the United States, it is 
estimated that 1.5-2% of future cancers may be attributable to radiation from CT 
studies [26]. Perhaps even more alarming are the results from a 2004 study 
which reported that 53% of radiologists, 91% of ER physicians, and 97% of 
patients did not believe that CT scans increased lifetime cancer risks [27]. While 
there has been increased awareness of the potential heightened cancer risk from 
CT studies, results such as these behoove the medical community to seek out 
non-ionizing radiation diagnostic tools such as magnetic resonance imaging 
(MRI) where applicable.  
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Magnetic Resonance Imaging (MRI) 
MRI is able to provide anatomical information similar to CT; however, MRI’s soft 
tissue differentiation ability is far superior to that of CT. In soft tissue organs and 
in areas with complex anatomy such as the brain, head and neck, and the pelvis, 
MRI allows for a more precise measurement of tumor location, size, and spread 
which all contribute to tumor staging [28]. MRI does not rely on ionizing radiation, 
but instead utilizes a powerful magnet and non-ionizing electromagnetic radiation 
in order to visualize structures within the body. The basic principle behind MRI is 
that human cells contain water molecules, the hydrogen atoms (protons) of which 
will align to the MRI’s magnetic field. This alignment will change when a source 
of electromagnetic radiation (in this case, a radio frequency) is applied, and the 
time it takes for the water molecules to return to their equilibrium (resting/normal) 
state is referred to as the relaxation time. Water molecules in different tissues of 
the body will have varying relaxation rates, and it is this difference (in addition to 
the actual proton density) that the MRI scanner can detect and use to create 
contrast between different structures and tissues. In addition, MRI is able to 
collect not only anatomical information, but also images of biophysical, 
pathophysiological, or functional properties of tissues which are not possible on 
CT [28]. Lymphoma, in particular, is a type of cancer which stands to benefit from 
MR imaging. 
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Diffusion-Weighted MRI (DWI) 
In recent years, the utility of MR imaging biomarkers in lymphoma patients has 
gained increased attention. MRI is capable of diffusion-weighted imaging (DWI-
MRI) which is sensitive to the motion of water molecules in tissue [29].   Although 
DWI received notoriety initially as a diagnostic tool for the early assessment of 
cerebral ischemia, recently, DWI has been explored in tumors [30-34].  This 
movement of water is referred to as Brownian motion, which is an inherent, 
random motion of molecules. By comparing different diffusion images within the 
same area, the apparent diffusion coefficient (ADC) can be calculated which is a 
quantitative measurement of water movement [29]. As with most malignancies, 
lymphoma lesions exhibit high cellularity (cellular density), which can restrict 
diffusion (thereby producing an elevated signal on DWI), and results in lower 
ADC values than tissue with lower and/or normal cellularity. The lower an ADC 
value is in a given area (tumor), the more restricted the diffusion is, and the 
higher the signal will be on DWI. Several studies have shown that increased 
cellular density is correlated with reduced ADC values derived from diffusion MRI 
[30-32, 35]. A few studies have compared the diagnostic accuracy of DWI to 
PET/CT for lymphoma staging and response to treatment with promising results 
[10, 36, 37]. In addition, there has been data to suggest that a strong inverse 
correlation (e.g. one value increases while the other decreases) exists between 
ADC values and PET-SUV in lymphoma patients [34].  Based on these previous 
studies, the complementary nature of MRI and PET promises to be of great 
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clinical importance in the staging and response assessment of lymphoma 
patients.  
 
Integrated PET/MR 
One limitation of PET-CT is that PET and CT information is acquired sequentially 
(one after another) and not simultaneously (at the same time). This can result in 
potential image fusion issues as well as inaccurate image interpretation due to 
misalignment [28]. This is particularly relevant when imaging the chest and 
abdomen due to resultant motion from the respiratory and digestive systems. 
Simultaneously acquired data also permits a temporal relationship (matched in-
time) to be established in which each data set is collected in exactly identical 
metabolic states.  While MRI is able to overcome several of the limitations of CT, 
MRI as a separate imaging tool and thus, involving a separate scanning session, 
will still result in this same issue of misalignment and will also add increased 
burden on patients since they will have to undergo two separate imaging 
examinations (PET-CT and MRI). 
 
The advent of an integrated whole-body PET/MR scanner in 2010 (Siemens 
Healthcare Biograph mMR) offers the possibility of obtaining PET’s metabolic 
(e.g. glucose metabolism, cell proliferation, etc.) information along with MRI’s 
anatomical and physiological (blood flow, vascular and tissue spaces, cellularity) 
information in one imaging session. Both types of information are currently used 
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in lymphoma staging [9]. This new integrated imaging modality also offers 
patients reduced radiation exposure compared to PET/CT by eliminating the CT 
component. The integration of PET and MR was made possible by the 
development of PET detectors that are able to function within a strong magnetic 
field, but do not interfere with the MR system. The MR-compatible PET photon 
detectors contain avalanche photodiodes (APD) instead of the conventional 
photomultipliers tubes (PMT). Recent studies have demonstrated that the 
sensitivity of the PET component of the Biograph mMR is comparable to, or 
possibly even higher, than that of conventional PET-CT scanners [38] [39]. 
 
There are currently three PET/MR models on the market: Ingenuity TF (Philips), 
Discovery PET/CT+MRI (GE Healthcare), and the Biograph mMR (Siemens). 
The latter PET/MR model is a truly integrated unit, capable of performing 
simultaneous PET and MRI [28]. The ability to acquire data simultaneously is of 
great clinical importance for numerous reasons. First, the temporally correlated 
measurements of early response to treatment can be assessed without a delay in 
time between two imaging modalities. This is particularly relevant for therapies 
with immediate effects (e.g. a drug with efficacy in hours rather than days) or 
studies involving continuously changing areas of the body (the digestive system). 
Second, simultaneously acquired data can also aid in MR-based motion 
correction as well as co-registration for PET image reconstruction [40]. Third, 
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acquiring MR and PET data in one session provides added comfort and 
convenience to the patient by only requiring one imaging session. 
 
Simultaneous PET/MR, albeit a promising imaging tool, is not without its own 
limitations and uncertainties [40]. Combined PET/MR faces unique challenges of 
attenuation correction of PET data. PET-CT data is corrected for attenuation by 
utilizing CT’s X-rays that are emitted to produce linear attenuation coefficients on 
a slice-by-slice basis. PET/MR, however, must rely on assigning attenuation 
coefficients by tissue class (based on MR data). This is challenging for many 
reasons, the largest of these being that MRI does not image cortical bone 
density.  Instead, MR based attenuation correction is based on proton density 
(hydrogen atoms).  Recent studies, however, have shown promising results for 
MR-based PET attenuation correction [41, 42]. While there is currently no 
established clinical indication for PET/MR use [28], this newly integrated imaging 
modality holds great diagnostic promise in the field of oncology and in particular, 
lymphoma. 
 
Study Purpose 
The purpose of this research study was to explore the clinical utility of a relatively 
new dual imaging modality (PET/MR) compared to the current clinical standard of 
care (PET/CT), in patients with lymphoma, while also investigating the potential 
decrease in overall radiation exposure. Specifically, does FDG-PET/MR have a 
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similar diagnostic performance to FDG-PET/CT and therefore, offer a 
comparable whole-body staging examination with an improved radiation safety 
profile in patients diagnosed with non-Hodgkin’s and Hodgkin’s lymphoma? 
 
The diagnostic performance of FDG-PET/MR compared to FDG-PET/CT was 
evaluated based on the primary outcome of the maximum standardized uptake 
value (SUVmax) correlation between the two imaging modalities. The secondary 
outcomes of interest were the correlation of DWI-derived ADC values to FDG-
PET/MR-derived SUVmax values, and the total received radiation dose per clinical 
FDG-PET/CT compared to decayed radiation dose at the time of the FDG-
PET/MR examination. 
 
Based on current literature, there has not been a prior study evaluating the 
diagnostic utility of simultaneous FDG-PET/MR compared to FDG-PET/CT in 
lymphoma patients. Given the potential added value (MR-derived imaging 
biomarkers, soft tissue resolution, bone marrow lesion detection, and temporal 
correlation of PET and MR data) of this new imaging modality in lymphoma 
patients and the current lack of available data, there is a strong need to address 
the above research question. Prior studies have shown the potential utility of 
DWI-derived ADC values in lymphoma staging [10, 36, 37]; however, other 
studies have reported a less promising utility [43, 44]. None of these studies, 
however, has utilized simultaneous PET/MR due to its availability only in recent 
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years. Two studies have compared PET/MR performance to PET/CT with 
optimistic results for the former imaging modality, but neither has investigated 
this comparison in the lymphoma patient population. [39, 45]. 
 
MATERIALS AND METHODS 
 
Subject Population 
Informed consent was waived in this IRB-approved retrospective analysis of data 
previously collected. All original data were collected between October 2011 and 
February 2013. Fifty-one patients with known or suspected tumors gave informed 
consent for an IRB-approved prospective cohort study. Inclusion criteria in the 
original cohort included age between 18 and 80 years old, ability to give written 
informed consent, ability to lie comfortably flat, and received a clinical PET or 
PET/CT examination and a same-day research FDG-PET/MR (Biograph mMR, 
Siemens, Germany) examination. Exclusion criteria included pregnancy, 
claustrophobia, and the presence of known contraindications for MRI including 
electrical or ferromagnetic implants.  
 
The inclusion criteria for this retrospective analysis included a confirmed 
diagnosis of non-Hodgkin’s or Hodgkin’s lymphoma. The exclusion criteria 
included failure to complete both a clinical FDG-PET/CT and same day research 
FDG-PET/MR. 
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Study Design 
This is a retrospective cross-sectional analysis of the data collected in the above 
prospective IRB-approved study.  
 
PET/CT Protocol  
All patients underwent a routine clinical PET-only or clinical PET/CT scan on a 
Siemens Biograph 64 (Siemens Healthcare, Germany). All patients fasted 
(except for water) for a 6 hour period before intravenous administration of the 
radiotracer [18F]fluordeoxyglucose (FDG), and blood glucose levels were 
checked to exclude hyperglycemia (>250 mg/dL) prior to FDG administration. 
The intravenously administered adult dose of FDG was based on body mass 
index (BMI): BMI <30 received 555MBq, BMI 31-44 received 740MBq, and BMI 
>45 received 925MBq. Imaging was performed 60 minutes after administration of 
FDG. Images were obtained from the base of the skull to the proximal one-third 
upper thigh.  
 
PET/MRI Protocol 
In all cases, imaging was performed with the Biograph mMR 3T scanner 
(Siemens Healthcare, Germany). Specially fabricated PET-compatible phased 
array coils (6-channel) were used to acquire the MR data. A 2-point Dixon 3D 
VIBE breath-hold T1 weighted sequence using the following parameters (iPAT 
factor 2, TR 3.6ms, TE1 1.225ms, TE2 2.45ms, matrix size 79x192, NEX=1, FOV 
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500mm, slice thickness 5.5mm, flip 10) was used to derive the attenuation 
correction (AC) map. This manufacturer-provided method allows the identification 
of four tissue types (fat, soft tissue, lung, background). Being difficult to segment 
from the MR data, bone tissue is treated as soft tissue for AC purposes. Coronal 
whole-body STIR was performed (iPAT factor 3, TR 3382-5631ms, TE 81-87ms, 
matrix 186x384, NEX=1, FOV 450mm, slice thickness 5.5mm, TI 220-230ms) in 
order to provide anatomic correlation. 
Whole-body DWI was performed using a single shot echo planar imaging 
technique (SSEPI) using the following parameters (iPAT factor 2, FOV 420, 
matrix 112x156, slice thickness 6mm, NEX 2, TE 68ms, TR 7800, TI 220ms (fat 
suppression), with b values including (0,50,800)). 
 
PET data was acquired using shallow free breathing from the upper thighs 
cephalad. Four to five bed positions were required to cover the entire abdomen 
and pelvis with ~10 minute data acquisition per bed position. PET axial field of 
view was 25.8cm. PET data was reconstructed using a 3D attenuation-weighted 
ordered subset expectation maximization (AW-OSEM) algorithm, with 3 iterations 
and 21 subsets, zoom=1, and Gaussian smoothing of 4mm FWHM. 
 
Maximum Standardized Uptake Value 
Image analysis was performed using OsiriX (OsiriX®, Geneva, Switzerland) 
software with fusion software embedded. Region of interest (ROI) analysis was 
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performed by consensus with a staff radiologist and a nuclear medicine 
technician on FDG-PET data fused with either CT or MRI demonstrating FDG 
avidity defined as one standard deviation (SD) above liver or mediastinum. The 
maximum standardized uptake value (SUVmax) of the lesions was measured on 
both FDG-PET/MR and FDG-PET/CT. 
 
Apparent Diffusion Coefficient (ADC) 
ADC parametric maps were generated online on the Siemens mMR post-
processing platform using a mono-exponential fit of the DWI raw data (b 
=0,50,800 data). Image analysis was performed using OsiriX (OsiriX®, Geneva, 
Switzerland) software with fusion software embedded. Region of interest (ROI) 
analysis was performed by a staff radiologist using FDG-PET data fused with 
axial DWI data. Analysis included visibility of lesion on DWI data at b=50 and 
b=800 sec/mm2, in addition to quantitative measures of SUV as compared to 
ADC values. 
 
Effective Radiation Dose 
The radiation dose received from whole-body CT was based on methodology 
published elsewhere [46]. Briefly, present generation CT scanners generate a 
value called the dose-length product (DLP) which is a measure of the total 
radiation delivered to a patient during a CT examination. The DLP was calculated 
from the length of the scan (cm) and the volume CT index (CTDIvol) which is an 
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index of the intensity of the radiation that the patient received: DLP = l (cm) x 
CTDIvol. Using the DLP value provided by the CT scanner as well as the number 
of slices and thickness per slice, an effective dose of the radiation received in 
milliSieverts (mSv) was obtained.  
 
The effective radiation dose received from whole-body PET was based on 
methodology published elsewhere [47]. Briefly, the amount of activity of 
radiotracer administered to a patient is a known value based on BMI. The degree 
of absorption of this activity varies depending on the organ referred to as the 
dose coefficient [48] and each organ was assigned a tissue weighting factor [49]. 
Effective radiation doses for each organ were calculated by multiplying the 
radiotracer activity by both the dose coefficient and tissue weighting factor for 
that organ. The effective whole-body radiation dose was calculated by the sum 
function of all of the individual organ effective dose values.  
 
Radioactivity at FDG-PET/MR 
Using the known activity of radiotracer administered to each patient, the time 
administered, and the known half-life of with [18F]fluordeoxyglucose (109.77 
min), the remaining activity at time of FDG-PET/MR scan (based on start time of 
PET acquisition) was calculated using GraphPad Radioactivity Calculator 
(GraphPad Software, La Jolla, CA).   This value was required in order to estimate 
the potential dose reduction from a unique PET/MR examination.   
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Statistical Analysis 
Nonparametric correlation analyses were performed using the Spearman rank 
correlation coefficient (rs) was calculated to examine the correlation between the 
SUVmax derived from FDG-PET/MR and FDG-PET/CT, as well as the correlation 
between ADCmin and SUVmax derived from FDG-PET/MR using GraphPad Prism 
6 (GraphPad Software, La Jolla, CA). Statistical significance was set at a p<0.05.  
Sample size was based on a power of 0.88 (beta of 0.12) and alpha of 0.05. In 
order to reject the null hypothesis (no relationship between two variables), a 
correlation coefficient of > 0.5 would need to be attained [50]. Correlation 
coefficient values of 0.5 – 1.00 indicate moderate to perfect strength of 
correlation. The power was set at 0.88 since it is known that the Spearman Rank 
Correlation Coefficient has 91% of the power of a Pearson Correlation Coefficient 
(0.8/0.91=0.88) [51]. Based on the above alpha, beta, and r=0.5 in order to reject 
the null hypothesis, the sample size needed was 29 lesions. Lesions and not 
patients were chosen as the sample since each lesion produced unique values 
on the two imaging modalities and were located in various regions of the body, 
which provided the best overall assessment of the diagnostic performance 
between FDG-PET/MR and FDG-PET/CT in lymphoma patients. For the purpose 
of this study, all FDG-avid lesions (n≥29) identified in eligible participants from 
the original cohort were included. 
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RESULTS 
 
Demographics & Clinical Parameters 
Of the 51 patients in the original data set, 17 patients (11 men and 6 women) had 
a confirmed diagnosis of non-Hodgkin’s or Hodgkin’s lymphoma. Two patients 
were excluded from this analysis due to incomplete FDG-PET/MR scans, leaving 
15 NHL and HL patients for analysis in this retrospective study. 
 
Patient demographics (sex, age, race), disease subtype, clinical exam (PET/CT 
or PET-only), number of FDG-avid lesions and number visualized on DWI are 
provided in Table 1 for all patients included in this analysis. Of the 15 subjects 
included in this analysis, 4 (26.67%) had a confirmed diagnosis of Hodgkin’s 
lymphoma and 11 (73.33%) had a confirmed diagnosis of non-Hodgkin’s 
lymphoma (3 mantle cell lymphoma, 2 diffuse large B cell lymphoma (DLBCL), 2 
marginal zone lymphoma, 2 follicular lymphoma, 1 mediastinal lymphoma, 1 
post-transplantation lymphoproliferative disease). The mean age was 
53.07±15.77 years (range: 30-80 years), and 60% (9/15) were male. Two 
subjects (13.33%) had received a clinical PET-only examination while the 
remaining thirteen subjects (86.67%) had received a clinical PET-CT 
examination. For the purpose of analysis, PET-only and PET/CT data were 
analyzed as one cohort. Four subjects did not have any abnormal FDG uptake. 
Of the remaining 11 patients, 37 FDG-avid lesions were identified, 25 of those 
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exhibited abnormal diffusion on DWI. All FDG-avid lesions were identified on 
both PET/MR and PET/CT. 
 
Table 1. Patient demographics and clinical parameters (DLBCL: Diffuse large B-cell 
lymphoma, HL: Hodgkin’s lymphoma, n/a: scan stopped early (excluded) 
 
Patient 
no. 
Sex 
(M/F) 
Age 
(years) 
Race Lymphoma Type No. of 
Lesions 
by PET 
No. of 
Lesions 
by DWI 
Lesion 
Location by 
PET 
1 M 52 White Mediastinal 
unclassified 
n/a n/a n/a 
2 F 80 White DLBCL 9 8 Lung (6), 
abdomen (2), 
breast (1) 
3 M 32 White HL 5 0 Lung (2), 
lymph nodes 
(2), bone (1) 
4 M 48 White Blastoid mantle 3 2 Neck (2), 
abdomen (1) 
5 M 57 White Mantle cell 1 0 Neck (1) 
6 F 32 White Mediastinal B-cell 0 -- -- 
7 M 71 White Marginal zone 0 -- -- 
8 M 32 Middle 
Eastern 
DLBCL 0 -- -- 
9 M 59 White Mediastinal B-cell n/a n/a n/a 
10 M 30 White Mantle cell 0 -- -- 
11 F 60 White HL 5 5 Peritoneal 
(3), spleen 
(1), abdomen 
(1) 
12 M 59 White Follicular 7 5 Muscle (3), 
subcutaneous 
(2), peritoneal 
(1), heart (1) 
13 F 59 White Marginal zone 1 0 Rectum (1) 
14 M 62 White HL 0 -- -- 
15 M 71 White Post-
transplantation 
lymphoproliferative 
disease 
4 4 Liver (3), 
peritoneal (1) 
16 F 53 White HL 1 0 Thyroid (1) 
17 F 50 White Follicular 1 1 Heart (1) 
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PET/MR SUVmax correlation to PET/CT SUVmax 
Thirty-seven FDG-avid lesions were analyzed. The mean SUVmax from PET/CT 
was on average lower than that of PET/MR with mean 4.59±2.72 g/ml (range: 
1.1-10.9 g/ml) and the mean PET/MR SUVmax being 8.50±4.57 g/ml (range: 2.8-
19.4; Table 2). An upward trend (before-after plot) of PET/MR SUVmax values 
compared to subject-matched PET/CT SUVmax values is demonstrated in Figure 
1a. Spearman rank correlation analysis comparing FDG-PET/MR SUVmax to 
FDG-PET/CT SUVmax showed a moderate to strong correlation, which was 
statistically significant (rs=0.84 (0.71, 0.92), p<0.0001; Figure 1b).  
 
Table 2: SUVmax from PET/MR and PET/CT (n=37) 
 
Imaging Modality SUVmax Mean  
(g/ml) 
SD Range 
PET/MR 8.50 4.57 2.8, 19.4 
PET/CT 4.59 2.72 1.1, 10.9 
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(a) 
(b) 
Figure 1. SUVmax correlation between PET/MR and PET/CT. (a) Before-after plot 
demonstrating upward trend of maximum SUV from PET/CT and matched PET/MR; (b) 
Correlation analysis of maximum SUV of FDG-PET/MR versus maximum SUV of FDG-
PET/CT demonstrating strong correlation (rs=0.84; p<0.0001). 
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ADCmin correlation to PET/MR SUVmax 
Twenty-five of the thirty-seven FDG-avid lesions (green arrow) also exhibited 
restricted diffusion on DWI (Figure 2a, green arrow), whereas twelve of the FDG-
avid lesions did not and were considered “missed” (Figure 2b, yellow arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
The mean ADCmin was 679.88±326.58mm2s-1 (range: 142-1472mm2s-1), and the 
mean SUVmax from PET/MR was 8.30±4.79 g/ml (range: 2.8-19.4). The mean 
Figure 2. Concordant and disconcordant lesions by PET and DWI. (a) Breast lesion 
with FDG avidity on PET/MR (green arrow); (b) Breast lesion with concordant restricted 
diffusion on DWI (green arrow); (c) Two mediastinal lesions exhibiting equal FDG avidity 
on PET/MR (green arrows); (d) Right mediastinal lesion exhibiting concordant restricted 
diffusion on DWI (green arrow). Left mediastinal lesion exhibiting decreased restricted 
diffusion (decreased signal on DWI) compared to right lesion (yellow arrow).  
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PET/MR SUVmax was not the same as the mean used to calculate the Spearman 
correlation above since only 25 (of 37) FDG-avid lesions were visualized on DWI. 
Spearman rank correlation analysis compared to FDG-PET/MR showed a weak 
to moderate correlation that was not statistically significant (r=0.35(-0.07, 0.66), 
p=0.09; Figure 3). 
 
 
 
 
 
Radiation dose exposure 
Thirteen subjects with completed clinical PET/CT examinations were included in 
the total FDG-PET/CT radiation dose analysis. Two of the patients in this study 
PET only examinations, and while a low dose of CT radiation was administered 
for attenuation correction purposes, the DLP values were not recorded per 
Figure 3. Correlation analysis of ADCmin compared to SUVmax.  Maximum SUV 
from FDG-PET/MR demonstrated a weakly positive correlation coefficient to 
ADCmin that was not statistically significant (r=0.35, p=0.09). 
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standard practice at this institution. The mean total radiation dose from PET/CT 
was 24.07±6.06mSv (range: 17.67-33.84mSv; Table 3, Figure 4). Of this total, 
the dose from CT accounted for approximately 50% with a mean CT dose of 
11.93±6.55mSv (range: 8.83-21.13mSv) and the mean FDG-PET dose was 
10.60±1.76mSv (range: 9.16-13.83mSv). In comparison, the mean radiation dose 
at time of FDG-PET/MR scan, corrected for decay over time, was 
2.87±0.092mSv (range: 1.54-5.00mSv) for the fifteen subjects who completed an 
FDG-PET/MR scan.  
 
Table 3: Ionizing radiation dose exposure (*: Decay-corrected radiation 
dose at time of FDG-PET/MR; **: Two patients had PET-only exams) 
 
Radiation 
Source 
N** Dose Mean  
(mSv) 
SD Range 
CT 13 11.93 6.55 8.83, 21.13 
FDG-PET 15 10.60 1.76 9.16, 13.83 
Total FDG-
PET/CT 
13 24.07 6.06 17.67, 33.84 
*FDG-PET/MR 15 3.41 1.12 1.86, 5.90 
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DISCUSSION 
 
In the present study, the diagnostic performance of FDG-PET/MR in lymphoma 
patients was compared to FDG-PET/CT using the maximum standardized uptake 
value and the apparent diffusion coefficient. In addition, the radiation dose profile 
between the two imaging modalities was compared. Based on current 
knowledge, no other study has compared FDG-PET/MR to FDG-PET/CT on the 
basis of SUVmax correlation, ADC to SUVmax correlation, and radiation dose in 
patients with non-Hodgkin's and Hodgkin’s lymphoma.  
 
Qualitatively, there was no discordance between FDG avid lesions comparing 
FDG PET/CT and FDG PET/MR.  This is critical when comparing the diagnostic 
performance and accuracy between these two technologies, as it conveys that 
Figure 4. Overall radiation exposure dose by radiation source.  
(*): FDG level corrected for decay at start of PET acquisition. 
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no changes in either staging or treatment response were observed, and therefore 
no change in management would have been conveyed.  Furthermore, the 
primary outcome in this study was the correlation of SUVmax derived from 
PET/MR to SUVmax from clinical PET/CT. The Spearman correlation coefficient 
was rs=0.85 (P<0.0001) which indicates a strongly positive correlation between 
the SUVmax derived from the two imaging modalities. This correlation coefficient 
is slightly lower than results reported by Drzezga et al. and McDermott et al. [39, 
52] who reported a very high correlation of rs=0.93 and rs =0.92, respectively, 
between mean SUVs in suspicious lesions in PET/MR and PET/CT. Interestingly, 
in that study, the SUV mean values for lesions on PET/CT were higher than 
those obtained for PET/MR (9.4±18.4% PET/CT > PET/MR). In contrast, the 
present study found higher on average SUV mean values for PET/MR compared 
to PET/CT (8.50±4.89 g/ml compared to 4.59±2.89 g/ml). Since there has only 
been one prior study directly comparing SUVmax values in PET/CT and PET/MR 
as mentioned above, there is no consensus on whether FDG uptake on PET/MR 
is typically higher or lower than on PET/CT. The amount of time elapsed from 
time of FDG administration to time of imaging has been shown to have a strong 
effect on the SUV measured [53]. A study by Hamberg et al. reported that SUV 
levels did not plateau for up to five hours post FDG administration in lung cancer 
patients [54]. While the same study has not been conducted in lymphoma 
patients, Hamberg et al.’s results support the higher PET/MR-derived SUV 
values reported in the present study Moreover, the absolute value of SUVmax is 
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not as clinically important as is the relative change from baseline or prior FDG-
PET.  
 
This study also evaluated the relationship between DWI-derived ADC values and 
SUVmax. In some previous studies, ADC values were reported to correlate 
inversely with SUVmax in both lymphoma and other malignancies such as cervical 
cancer [30, 32] [55]. Conversely, Wu et al. [56] showed that there was no 
correlation between ADC values and SUVmax in non-Hodgkin’s lymphoma. All of 
these studies, however, relied on diffusion-MRI and PET data obtained from two 
different imaging modalities, and hence, two different imaging sessions. The 
results presented in this study do not support a strong correlation between ADC 
and SUVmax. Analysis of these two measurements resulted in a Spearman rank 
coefficient of rs=0.35 (p<0.09), which was not statistically significant. It is possible 
that in the quest to overcome the numerous challenges of combining MR and 
PET imaging, the absolute value of the apparent diffusion coefficient or the 
maximum standardized uptake value may be skewed in the process. As reported 
above, the observed SUVmax values from simultaneous PET/MR were higher on 
average than those reported by Drzezga et al. [39]. This relative difference could 
potentially reduce the presence of an inverse correlation between two variables, 
and could explain the lack of strong correlation observed.   
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It should be noted that not all FDG-avid lesions exhibited abnormal diffusion on 
DWI and as a result, ADC values could not be obtained for those lesions. The 
ADC results presented in this study were only abnormal in 25/37 identified 
lesions. Of the twelve “missed” lesions, four were located in the chest (5/12 in 
neck, 1/12 in abdomen, 1/12 in muscle, 1/12 in thyroid). This variation in DWI is 
consistent with previous research in which signal loss and motion artifact 
occurred in the chest region due to respiration [57]. While this study did not 
support a correlation between ADC and SUVmax, it is important to acknowledge 
the potential diagnostic utility of these factors individually when staging and 
treating lymphoma patients.  
 
It should also be noted that these lymphoma patients were at various stages of 
their treatment.  None of the patients were at their baseline (pre-treatment) 
measurement.  Therefore, this lack of correlation may be indicative and 
supportive that their measures were reflective of two different physiologic 
qualities (i.e. metabolism (FDG) and cellular density (ADC)).  This may support 
their complementary nature and reflect another means of stratification of this 
patient population.  Furthermore, since DWI is truly non-invasive, it comes at no 
risk for the patient. 
 
The overall radiation dose received from one clinical FDG-PET/CT was 
estimated in this study. The mean radiation dose received was 24.07±6.06mSv. 
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This amount of radiation exposure is approximately equal to 6-7 years of natural 
background radiation [58] and at the present time, poses an unknown cancer 
risk.  While this is not particularly relevant in many oncologic subtypes, given the 
average lymphoma patient’s age and lifetime mortality risk from their cancer, it is 
particularly relevant in this sub-population, many of whom are younger (even 
children), and many of whom are deemed “cured” after systemic chemotherapy. 
For those still with FDG avid disease, the International Harmonization Project 
criteria recommends baseline and post-therapeutic intervention PET/CT scans 
for NHL and HL patients [9]. Depending on the response to treatment, lymphoma 
patients are likely to have several PET/CT scans per year until partial remission 
(PR) and/or complete remission (CR) is achieved. This number, and as a result, 
a patient’s radiation exposure will increase if relapse occurs. While 80% of 
relapse cases can be identified clinically, subsequent imaging is required to 
determine restaging [9, 59]. Since radiation exposure is cumulative, a patient 
may be exposed to the equivalent of up to twenty years of background radiation 
in a single year due to numerous PET/CT examinations. 
 
In comparison, the remaining level of radioactivity (decay due to time delay 
between scans) at the time of the PET/MR scan had a mean of 3.28±0.92mSv. 
While this measurement is an estimate of the actual radiotracer dose that is 
currently used clinically for FDG-PET, it is suggestive of a potential reduction in 
FDG radiation exposure for oncology, in particular children and lymphoma, 
 31 
patients in the future. It is possible that the high sensitivity of PET/MR can 
ultimately lead to a lower radiation dose to a level somewhere between the 
decayed-corrected FDG mean reported in this study and the mean clinical FDG-
PET dose administered. This idea is supported by the fact that all FDG-avid 
lesions on PET/CT were identified on PET/MR despite the lapse in time and 
radiation decay, in addition to the strong correlation of PET-MR SUVmax to PET-
CT SUVmax; however, the validity of this statement is out of the scope of this 
study and it remains to be seen if and by how much FDG-PET doses can be 
reduced while maintaining high sensitivity and specificity.  Since the CT radiation 
dose comprised approximately 50% of the total FDG-PET/CT in this study, 
removing this source of ionizing radiation while leaving the FDG-PET dose the 
same would still result in a significant reduction in overall radiation exposure for 
the patient. Furthermore, it should be noted that this Institution uses CT radiation 
levels that are 30% to 95% less than reference levels used by the National 
Council on Radiation Protection [60]. This supports the possibility of an even 
larger reduction (more than 50%) in radiation exposure by utilizing PET/MR in 
place of PET/CT for lymphoma staging and response to treatment across the 
United States and abroad. Due to the cumulative nature of radiation exposure 
and the risk of cancer induced from radiation [47], the medical community should 
carefully weigh the risk-benefit ratio when ordering diagnostic examinations 
involving ionizing radiation such as PET/CT. This is particularly relevant as 
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further studies evaluate the diagnostic utility of simultaneous PET/MR and the 
technology gains further and wider acceptance. 
 
A major strength of this study is that it was able to explore the association of a 
quantitative metabolic measurement from truly simultaneous PET/MR with 
PET/CT. This is only the second study to explore this potential relationship, and it 
is the only study to focus on lymphoma patients. Furthermore, there were no 
FDG-avid lesions detected on PET/CT that were missed on PET/MR, and  strong 
correlation coefficient reported here is similar to the one reported by Drzezga et 
al.[39].  
 
In addition, the demographics demonstrated in this study are representative of 
lymphoma patients in the United States. Compared to 85% of lymphoma patients 
having the non-Hodgkin’s subtype, this study included 73.33% NHL patients, with 
mean age of 53.07±15.77 years (accounting for the bimodal distribution of HL 
patients), predominantly white, and 60% (9/15) were male which equals the 1.5:1 
incidence ratio of men to women. 
  
A notable limitation of this study is the number of available lymphoma patients 
who had received a clinical FDG-PET/CT and research FDG-PET/MR. 
Specifically, the number of FDG-avid lesions was variable for each patient, 
ranging from no abnormal FDG uptake to up to ten identifiable lesions. While it is 
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difficult to speculate how increasing the n would change the results of this study, 
a larger study group would allow for stratification by lesion location (chest, neck, 
pelvis) or lymphoma subtype which could provide added value for PET/MR 
clinical indications. Furthermore, while a statistical adjustment was not made for 
the number of lesions per patient, a future study might want to address this point 
to remove this potential confounder. Another limitation is that the lymphoma 
patients included in this analysis were at various stages of their treatment, which 
could account for those patients with no FDG-avid lesions (if PET/CT was post-
treatment), and be a potential source of poor correlation between SUV and ADC. 
The radiologist who determined the ROIs used to calculate the SUVmax and ADC 
values was not blinded to this study; however, designing such a blinded study 
poses a great challenge as the anatomic images from PET/CT and PET/MR 
images are visually different despite the similarities between the PET images. 
Another potential limitation is the MR-based attenuation correction which may 
vary in accuracy based upon the body region, and is an area for further 
investigation. Lastly, a potential limitation in this study is the inclusion of 
standardized uptake values from PET-only examinations; however, a low-dose 
CT is used to correct for attenuation and is equivalent to the attenuation 
correction that occurs in PET/CT at this Institution. 
   
Integrated PET/MR is a relatively new imaging modality with numerous potential 
applications in the field of oncology and areas yet to be identified. The limited 
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numbers of studies investigating the diagnostic utility of such an integrated 
system have been promising thus far, and further studies are warranted. Within 
the indication of NHL and HL, a larger prospective cohort study aimed at 
validating the diagnostic utility of PET/MR compared to PET/CT should be 
undertaken. Specifically, the sensitivity and specificity of FDG-avid lesion 
detection as well as the complementary nature of diffusion-MR should be 
evaluated further.  Lymphoma patients stand to benefit directly from the 
availability of clinical PET/MR scans compared to PET/CT due to the reduced 
levels of ionizing radiation, and thus, may benefit from a lowered lifetime risk of 
cancer. 
 
CONCLUSION 
 
The purpose of this research study was to explore the clinical utility of a relatively 
new dual imaging modality (FDG-PET/MR) compared to the current clinical 
standard of care (FDG-PET/CT), while also investigating the potential decrease 
in overall radiation exposure. The primary outcome in this study was the 
maximum standardized uptake value (SUVmax) correlation between the two 
imaging modalities. The secondary outcomes of interest were the correlation of 
DWI-derived ADC values to FDG-PET/MR-derived SUVmax values, and the total 
received radiation dose per clinical FDG-PET/CT compared to decayed radiation 
dose at FDG-PET/MR. The Spearman rank correlation coefficient was used to 
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determine the correlation between SUVmax derived from FDG-PET/MR and FDG-
PET/CT, resulting in a ranked correlation coefficient of rs=0.84 (0.71, 0.92), 
p<0.0001. The correlation of ADCmin compared to SUVmax derived from FDG-
PET/MR was also calculated using the Spearman rank correlation coefficient, 
resulting in a ranked correlation coefficient of rs=0.35 (-0.07, 0.66), p=0.09.  
 
The results of this study support the conclusion that the diagnostic performance 
of FDG-PET/MR compared to FDG-PET/CT as measured by SUVmax is similar 
between the two imaging modalities, and therefore, offers a comparable whole 
body staging examination. However, the results of this study do not support the 
conclusion that ADCmin is correlated to SUVmax in an integrated PET/MR scanner. 
Fifty percent of the high levels of ionizing radiation received from combined 
PET/CT are attributable to radiation from CT alone, and eliminating this 
component in an integrated PET/MR system supports the conclusion that 
PET/MR use can lead to a decrease in a patient’s overall radiation exposure. 
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